Aarti Drugs Q1 FY27: Revenue Up 19%, EBITDA Soars 30% YoY
Aarti Drugs reported Q1 FY27 consolidated revenue of ₹703.6 crore, up 19% YoY. EBITDA increased 30% to ₹96.9 crore with margins at 13.8%. PBT grew 35% YoY to ₹69.2 crore. The company highlighted strong operational performance, improved realisations, and capacity expansion plans.
The results show positive growth, but the impact is moderate as it's a routine quarterly update and does not involve extraordinary events like mergers, acquisitions, or significant new product launches with immediate large-scale financial impact.
The company reported strong year-on-year growth in revenue and EBITDA, along with improved margins. Management commentary expresses confidence in the demand outlook and future growth drivers.
Aarti Drugs Limited announced its financial results for the first quarter of FY27 (Q1 FY27), reporting a significant 19% year-on-year increase in total revenue, reaching ₹703.6 crore. The company's EBITDA also demonstrated strong growth, rising by 30% YoY to ₹96.9 crore, with EBITDA margins improving by 120 basis points to 13.8%. Profit Before Tax (PBT) grew by 35% YoY to ₹69.2 crore. The company noted that Q1 FY27 EBITDA and PBT include an additional expense of approximately ₹2 crore due to a CWIP write-off.
The management commentary highlighted a strong operational and financial performance driven by volume growth and improved realisations in the API & Speciality Chemicals portfolio. The company is seeing a recovery in the pricing environment and expects continued growth from its USFDA and UK-approved facilities, supporting expansion in regulated markets. The Sayakha facility is progressing with its planned ramp-up, operating at nearly 65% utilization. Furthermore, Aarti Drugs is expanding its oral solid dosage (OSD) capabilities in Baddi, Himachal Pradesh, aiming to double production capacity.
Operationally, the focus remains on improving capacity utilization, optimizing product mix, and enhancing manufacturing efficiencies. The company is also investing in process optimization, capacity enhancement, backward integration, and operational efficiencies to strengthen margin performance. The demand outlook for the product portfolio is described as encouraging, with a continued focus on regulatory compliance to capitalize on opportunities.
What to do with a filing like this
Aarti Drugs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.